Research from Redeye, Redeye AB

Redeye

Redeye is the next generation equity research and investment banking company, specialized in Life Science and Technology. We are the leading provider of Corporate Broking and Corporate Finance in these sectors.

Our clients are innovative growth companies in the Nordics and we use a unique Rating model based on a value based investment philosophy. Redeye was founded 1999 in Stockholm and is regulated by the Swedish Financial Authority (Finansinspektionen). 

Expertise in Denmark, Finland, Norway and Sweden.

Research from Redeye

Redeye AB

Specialists in innovative and fast-growing Nordic companies within Life Science and Technology.

Redeye is the next generation equity research and investment banking company, specialized in Life Science and Technology. We are the leading provider of Corporate Broking and Corporate Finance in these sectors.

Our clients are innovative growth companies in the Nordics and we use a unique Rating model based on a value based investment philosophy. Redeye was founded 1999 in Stockholm and is regulated by the Swedish Financial Authority (Finansinspektionen).

Equity Bottom-Up

<ul><li>Redeye leaves a comment following Alzinova’s announcement that the FDA has granted Fast Track Designation (FTD) for its lead candidate ALZ-101.</li><li>We view this as an important regulatory milestone that not only validates the strength of the clinical and mechanistic data generated to date but also has the potential to accelerate development timelines.</li><li>Moreover, we believe the designation strengthens Alzinova’s position in ongoing partnership discussions ahead of the planned phase II initiation.</li></ul>

Redeye leaves a comment following Alzinova’s announcement that the FDA has granted Fast Track Designation (FTD) for its lead candidate ALZ-101.We view this as an important regulatory milestone that not only validates the strength of the clinical and mechanistic data generated to date but also has the potential to accelerate development timelines.Moreover, we believe the designation strengthens Alzinova’s position in ongoing partnership discussions ahead of the planned phase II initiation.

Alzinova: ALZ-101 granted Fast Track Designation